Validating the allogeneic stem cell transplantation disease risk index: Sample size, follow-up, and local data are important

Abstract

Background. Reporting allogeneic hematopoietic stem cell transplantation (alloHSCT) outcomes by disease and disease stage can limit statistical power. Recently, the disease risk index (DRI) was developed and validated to stratify clusters of patients with various combinations of disease and stage for overall survival (OS), progression-free survival (PFS), and cumulative incidence of relapse (CIR). However, the DRI has not been tested for smaller cohorts or cohorts with shorter follow-up.Methods. Data from recipients of a first alloHSCT between 2000 and 2011 (n=466; median follow-up, 55.2 months) were extracted from our database. Each patient was assigned to one of four risk categories accord..